Patents by Inventor Joshua T. JOHNSTONE

Joshua T. JOHNSTONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONS
    Publication number: 20230090653
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Application
    Filed: June 3, 2022
    Publication date: March 23, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Stephen D. COLLINS, Peter J. GOLDSTEIN, Joshua T. JOHNSTONE
  • USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONS
    Publication number: 20200155456
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 21, 2020
    Inventors: Stephen D. COLLINS, Peter P. GOLDSTEIN, Joshua T. JOHNSTONE
  • MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF HUPERZINE AND METHODS OF USING THE SAME
    Publication number: 20180333365
    Abstract: The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Inventors: Stephen D. COLLINS, Peter GOLDSTEIN, Joshua T. JOHNSTONE